Cited by 25

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Hepatic Overexpression of Endothelial Lipase Lowers High-Density Lipoprotein but Maintains Reverse Cholesterol Transport in Mice: Role of Scavenger Receptor Class B Type I/ATP-Binding Cassette Transporter A1-Dependent Pathways

Takiguchi, Shunichi, Ayaori, Makoto, Yakushiji, Emi, Nishida, Takafumi, Nakaya, Kazuhiro, Sasaki, Makoto, Iizuka, Maki, Uto-Kondo, Harumi, Terao, Yoshio, Yogo, Makiko, Komatsu, Tomohiro, Ogura, Masatsune, Ikewaki, Katsunori·2018·Arteriosclerosis, Thrombosis, and Vascular Biology

Abstract

Objective—: Reverse cholesterol transport (RCT) is a major mechanism by which HDL (high-density lipoprotein) protects against atherosclerosis. Endothelial lipase (EL) reportedly reduces HDL levels, which, in theory, would increase atherosclerosis. However, it remains unclear whether EL affects RCT in vivo. Approach and Results—: Adenoviral vectors expressing EL or luciferase were intravenously injected into mice, and a macrophage RCT assay was performed. As expected, hepatic EL overexpression markedly reduced HDL levels. In parallel, plasma 3 H-cholesterol counts from the EL-expressing mice decreased by 85% compared with control. Surprisingly, there was no difference in fecal 3 H-cholesterol excretion between the groups. Kinetic studies revealed increased catabolism/hepatic uptake of 3 HDL-cholesteryl ether, resulting in no change in fecal HDL-cholesteryl ester excretion in the mice. To explore underlying mechanisms for the preservation of RCT despite low HDL levels in the EL-expressing mice, we investigated the effects of hepatic SR-BI (scavenger receptor class B type I) knockdown. RCT assay revealed that knockdown of SR-BI alone reduced fecal excretion of macrophage-derived 3 H-cholesterol. Interestingly, hepatic EL overexpression under SR-BI inhibition further attenuated fecal tracer counts as compared with control. Finally, we observed that EL overexpression enhanced in vivo RCT under pharmacological inhibition of hepatic ABCA1 (ATP-binding cassette transporter A1) by probucol. Conclusions—: Hepatic EL expression compensates for reduced macrophage-derived cholesterol efflux to plasma because of low HDL levels by promoting cholesterol excretion to bile/feces via an SR-BI pathway, maintaining overall RCT in vivo. In contrast, EL-modified HDL might negatively regulate RCT via hepatic ABCA1. Despite extreme hypoalphalipoproteinemia, RCT is maintained in EL-expressing mice via SR-BI/ABCA1-dependent pathways.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/atvbaha.118.311056

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • EL belongs to the same lipase family as LPL, but targets phospholipids on the shell of high-density lipoproteins (HDL), leading to decreased HDL levels.

    “EL belongs to the same lipase family as LPL, but targets phospholipids on the shell of high-density lipoproteins (HDL), leading to decreased HDL levels (119–122).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 43

  1. 10.1080/07853890310020635 · DOI
  2. 10.1038/nrcardio.2009.94 · DOI
  3. 10.1056/NEJMoa1001689 · DOI · Paper page
  4. 10.1016/S0022-2275(20)30466-1 · DOI · Paper page
  5. 10.1172/JCI16306 · DOI
  6. 10.1172/JCI16146 · DOI
  7. 10.1172/JCI37176 · DOI
  8. 10.1074/jbc.M406360200 · DOI
  9. 10.1194/jlr.M500366-JLR200 · DOI
  10. 10.1161/CIRCGENETICS.111.962613 · DOI
  11. 10.1016/j.atherosclerosis.2010.04.004 · DOI
  12. 10.1172/JCI25327 · DOI · Paper page
  13. 10.1074/jbc.274.4.2366 · DOI
  14. 10.1161/CIRCULATIONAHA.110.009704 · DOI
  15. 10.1074/jbc.M304367200 · DOI
  16. 10.1038/35042675 · DOI · Paper page
  17. 10.5551/jat.14.133 · DOI
  18. 10.1161/CIRCRESAHA.107.151746 · DOI
  19. 10.1161/01.ATV.0000193513.29074.52 · DOI
  20. 10.1161/CIRCRESAHA.109.206615 · DOI
  21. 10.1007/s11745-001-0843-0 · DOI
  22. 10.1016/S0026-0495(98)90064-6 · DOI
  23. 10.1073/pnas.222421399 · DOI
  24. 10.1074/jbc.M502264200 · DOI · Paper page
  25. 10.1161/01.CIR.0000092889.24713.DC · DOI
  26. 10.1074/jbc.M302181200 · DOI
  27. 10.1074/jbc.M807683200 · DOI
  28. 10.1161/ATVBAHA.109.199158 · DOI
  29. 10.1126/science.204996 · DOI
  30. 10.1194/jlr.R024075 · DOI
  31. 10.1016/j.atherosclerosis.2015.06.028 · DOI
  32. 10.1161/ATVBAHA.113.301373 · DOI · Paper page
  33. 10.1161/CIRCULATIONAHA.107.707349 · DOI
  34. 10.1161/01.ATV.0000259357.42089.dc · DOI
  35. 10.1097/MOL.0b013e328357ba61 · DOI
  36. 10.1016/j.bbalip.2013.01.003 · DOI
  37. 10.1161/CIRCRESAHA.110.219188 · DOI
  38. 10.1042/BJ20020306 · DOI
  39. 10.1074/jbc.M101726200 · DOI · Paper page
  40. 10.1074/jbc.272.20.13242 · DOI
  41. 10.1161/ATVBAHA.108.176487 · DOI
  42. 10.1194/jlr.M300231-JLR200 · DOI
  43. 10.1194/jlr.M020743 · DOI

Cited by

Sorted by citations

Metadata

Authors
Takiguchi, S., Ayaori, M., Yakushiji, E., Nishida, T., Nakaya, K., Sasaki, M., Iizuka, M., Uto-Kondo, H., Terao, Y., Yogo, M., Komatsu, T., Ogura, M., & Ikewaki, K.
Affiliations
  • From the Division of Anti-Aging and Vascular Medicine, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan (S.T., M.A., E.Y., T.N., K.N., M.S., M.I., H.U.-K., Y.T., M.Y., T.K., K.I.)
  • Department of Molecular Innovation in Lipidology, National Cerebral and Cardiovascular Center, Osaka, Japan (M.O.).
Venue
Arteriosclerosis, Thrombosis, and Vascular Biology
Published
2018-07
Volume
38
Issue
7
Pages
1454-1467
ISSN
  • 1079-5642
  • 1524-4636
Cited by
25
References
2
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review